Zimbabwe has declined a significant US health deal worth $367m (272 million pounds) over five years due to the United States' insistence on confidential data.
This rejection became public following a official document dated December was leaked, which showed Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
An official spokesman has since stated that the United States was seeking genetic material for research and commercial purposes but was not willing to guarantee the resulting advantages from any future vaccines.
"We are forced to start the challenging and unfortunate task of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had provided more than $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for continued talks to reach a deal suitable to both sides so the nation's critical HIV programme can continue.
Wider Context
This rejection comes after a comparable case in neighbouring Kenya, where a high court suspended a related health funding agreement following concerns were filed about the security of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had managed aid for the US government, but Trump argued its expenditure was "wasteful" and his administration was seeking direct bilateral deals to boost transparency and responsibility.
As per reports, 16 nations in Africa have to date signed these new health pacts, representing more than $18.3bn in committed funds.
Details of the Rejected Agreement
The money for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration might have yielded significant benefits for the people of Zimbabwe, especially the 1.2 million presently on HIV treatment via American-funded initiatives," Tremont added.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Our nation was requested to share its biological resources and data over an extended period, without any corresponding promise of benefiting from any medical innovations – like new medicines or tests – that might result from that provided information," Mangwana explained.
"Put simply, our country would supply the raw materials for medical research with no assurance that the resulting innovations would be available to our population if a new disease outbreak arise."
National Interest and International Frameworks
Mangwana further said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending systems previously set up through the global organization.
The spokesperson cited its Pandemic Benefit-Sharing framework created to deal with potential global health emergencies.
"This mechanism is intended to guarantee that when a nation contributes its samples, the benefits – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how future co-operation might be designed in a manner that honours the independence and interests of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the government's concerns, but suggested that negotiations need to persist since much of the country's HIV programmes depended on external financing.
"In cases where technical issues arise, including those relating to data governance or agreement terms, these can frequently be addressed through technical clarification and mutually agreed protections," it added.
The situation underscores the complex debate between accepting much-needed international aid and safeguarding a country's data in an ever more data-driven world.